Suppr超能文献

肠-肝轴在非酒精性脂肪性肝病中的作用

Role of Gut-Liver Axis in Non-Alcoholic Fatty Liver Disease.

作者信息

Yaghmaei Hessam, Taromiha Amirmahdi, Nojoumi Seyed Ali, Soltanipur Masood, Shahshenas Sina, Rezaei Mahdi, Mirhosseini Seyed Mohsen, Hosseini Seyyed Mohammad, Siadat Seyed Davar

机构信息

Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.

Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran.

出版信息

Iran Biomed J. 2025 Jan 1;29(1 & 2):1-8. doi: 10.61186/ibj.4212.

Abstract

Non-alcoholic fatty liver disease (NAFLD) has emerged as a significant global health problem, mainly due to the increasing prevalence of obesity and metabolic syndrome. The gut microbiota plays an essential role in the development of NAFLD through the gut-liver axis. Dysbiosis of. the gut microbiota (GM) is associated with the pathogenesis of NAFLD. Dietary choices and other lifestyle factors influence the composition of the GM and contribute to the development of NAFLD. At the phylum level, individuals with NAFLD show an increased level in Actinobacteria and Firmicutes, while Verrucomicrobia, Thermus, Proteobacteria, Lentiphaerae, and Fusobacteria are found to be decreased. Several genera, including Faecalibacterium and Akkermansia, exhibit alterations in NAFLD and are linked to disease progression. Modulating the GM through prebiotics, probiotics, or fecal microbiota transplantation represents a promising therapeutic strategy for NAFLD. This review summarizes the current understanding of GM changes in NAFLD, focusing on findings from both human and animal studies.

摘要

非酒精性脂肪性肝病(NAFLD)已成为一个重大的全球健康问题,主要原因是肥胖和代谢综合征的患病率不断上升。肠道微生物群通过肠-肝轴在NAFLD的发展中起重要作用。肠道微生物群(GM)的失调与NAFLD的发病机制有关。饮食选择和其他生活方式因素会影响GM的组成,并促进NAFLD的发展。在门水平上,NAFLD患者的放线菌门和厚壁菌门水平升高,而疣微菌门、栖热菌属、变形菌门、厌氧绳菌纲和梭杆菌门则减少。包括粪杆菌属和阿克曼氏菌属在内的几个属在NAFLD中表现出变化,并与疾病进展有关。通过益生元、益生菌或粪便微生物群移植来调节GM是一种很有前景的NAFLD治疗策略。这篇综述总结了目前对NAFLD中GM变化的理解,重点是来自人类和动物研究的结果。

相似文献

5
Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.肠道微生物群:非酒精性脂肪性肝病的新治疗靶点。
Expert Rev Gastroenterol Hepatol. 2019 Mar;13(3):193-204. doi: 10.1080/17474124.2019.1569513. Epub 2019 Jan 25.
9
Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease.非酒精性脂肪性肝病患者的肠道菌群失调。
Hepatobiliary Pancreat Dis Int. 2017 Aug 15;16(4):375-381. doi: 10.1016/S1499-3872(17)60019-5.

本文引用的文献

6
Human gut microbiome: hopes, threats and promises.人类肠道微生物组:希望、威胁和承诺。
Gut. 2018 Sep;67(9):1716-1725. doi: 10.1136/gutjnl-2018-316723. Epub 2018 Jun 22.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验